Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 28Gastrointestinal Stromal Tumors 19Leukemia 16Leukemia, Myeloid, Chronic-Phase 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Leukemia, Myeloid 5Bronchiolitis Obliterans Syndrome 5Bone Marrow Diseases 5Philadelphia Chromosome 3Hematologic Diseases 3Sarcoma 2Neoplasms by Histologic Type 2Hematologic Neoplasms 2Translocation, Genetic 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Piebaldism 1Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) 1Pathologic Processes 1Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Lymphoproliferative Disorders 1Lymphatic Diseases 1Leukemia, Lymphoid 1Leukemia, Biphenotypic, Acute 1Immunoproliferative Disorders 1Immune System Diseases 1Graft vs Host Disease 1Glioblastoma 1Burkitt Lymphoma 1

Interventions

Rituximab 2Cytarabine 2ponatinib 1ibrutinib 1ibritumomab tiuxetan 1cirmtuzumab 1amonafide 1acalabrutinib 1Vincristine 1Prednisone 1Melphalan 1Imatinib Mesylate 1Etoposide 1Doxorubicin 1Daunorubicin 1Cyclophosphamide 1Carmustine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Lymphatic Diseases × Imatinib Mesylate × Clear all
NCT01650805 2014-11-17

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Ariad Pharmaceuticals

Phase 3 Terminated
307 enrolled 11 charts
LymphoidMyeloidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Leukemia, Myeloid, Lymphatic Diseases, Lymphoproliferative Disorders, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡